Welcome to Lannett.investorroom.com - Lannett Company

lannett.investorroom.com

Description: Lannett Investor Room. Lannett is a US-based pharmaceuticals company manufacturing and/or commercially marketing over 100 generic pharmaceutical...

Google PR 0

Trustworthiness Unknown
Avg. Daily Visitors N/A

Child Safety Unknown
Avg. Daily Pageviews N/A

Privacy Unknown

Lannett Company - Investor Relations

Lannett.investorroom.com: get to the top rated Lannett Investor Room pages and content popular with India-based Lannett.investorroom.com users or check the following digest to find out more. Lannett.investorroom.com is a malware-free website without age restrictions, so you can safely browse it. It seems that Lannett.investorroom.com team has yet to grow their social media activity, as the major social networks contain little or no materials related to this domain. Lannett.investorroom.com is hosted with CloudFlare, Inc. in United States. Lannett Investor Room traffic is not yet estimated by Alexa.

Visit lannett.investorroom.com

Domain info

Location:	United States
Registrant:	Not Disclosed Not Disclosed (Not Disclosed)
Hosted by:	CloudFlare, Inc.
Registrar:	CSC Corporate Domains, Inc.
Subnetworks:	104.17.202.159, 104.17.203.159, 104.17.204.159, 104.17.205.159, 104.17.206.159

Social Media Activities

Facebook likes: -
Twitter mentions: -
Google pluses: -
LinkedIn mentions: -
Pinterest pins: -
StumbleUpon views: -

Web Safety

This website is malware-free.
Status ok

See Google Transparency Report

Sites associated with the same registrant

Whois

Expand

Lannett.investorroom.com popular pages to visit

Lannett In Discussions To Re-Establish Business Relationship With Key Customer - Mar 14, 2016 Lannett In Discussions To Re-Establish Business Relationship With Key Customer PHILADELPHIA, March 14, 2016 /PRNewswire/ --Â Lannett Company, Inc. (NYSE: LCI) today announced that its wholly owned sub...

Lannett Company - Investor Relations Lannett is a US-based pharmaceuticals company manufacturing and/or commercially marketing over 100 generic pharmaceutical products.

Lannett Completes Repurchase Of Remaining $200 Million Of 12% Senior Notes - Jun 20, 2016 Lannett Completes Repurchase Of Remaining $200 Million Of 12% Senior Notes --Overcomes Volatile Market to Achieve Significant Interest Savings-- PHILADELPHIA, June 20, 2016 /PRNewswire/ --Â Lannett C...